Studies on pyrazinoylguanidine

Pharmacology

Volumn 54, Issue 5, 1997, Pages 256-260

  Follansbee, Mark H ^a   Beyer, Karl H ^a   Vesell, Elliot S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Cataracts; Diabetes mellitus; Eye; Pyrazinoylguanidine; STZ rats

Indexed keywords

GUANIDINE DERIVATIVE; PYRAZINE DERIVATIVE; PYRAZINOYLGUANIDINE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATARACT; CATARACTOGENESIS; CONTROLLED STUDY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; CATARACT; DIABETES MELLITUS, EXPERIMENTAL; GUANIDINES; HYPOGLYCEMIC AGENTS; MALE; ODDS RATIO; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

EID: 0030871673     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139493     Document Type: Article

References (17)

1. Hcyningcn R van: Experimental studies on cataract. Invest Ophthalmol 1976; 15:685-697.
2. A-Rahim YI. Beyer KH Jr. Vcsell ES: Studies on pyrazinoylguanidine. 4. Characterization of metabolic effects in diabetic rats. Pharmacology 1996:52:135-144.
3. Chambers CE. Vesell ES. Helm C. Passananti GT, Beyer KH Jr: Pyrazinoylguanidine: Antihypertensivc, hypocholestérolémie, and renin effects. J Clin Pharmacol 1992:32: 1128-1134.
4. Vcsell ES. Chambers CE. Passananti GT. Demers LM. Beyer KH Jr: Effects of pyrazinoylguanidine on the glucose-fatty acid cycle in normal subjects and patients with non-insu-lin-dependent diabetes mellitus. J Clin Pharmacol 1993;33:823-831.
5. Vcsell ES. Chambers CE, DeAngelo-Seaton T. Passananti GT. Demers LM, Beyer KH Jr: Pyrazinoylguan-idinc downregulates the glucose-fatty acid cycle in hypertensive, hyperinsulinémie diabetic patients. J Clin Pharmacol 1994;34:1234-1245.
6. Clements RS Jr. Bell DS: Complications of diabetes: Prevalence, detection. current treatment, and prognosis. Am J Med 1985:79(suppl 5A):2-7.
7. Herman WH. Teutsch SM, Sepc SJ, Sinnock P, Klein R: An approach to the prevention of blindness in diabetes. Diabetes Care 1983:6:608-613.
8. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1996:329:977-986.
9. Kinoshita JH: Mechanisms initiating cataract formation. Invest Ophthalmol 1974:13:713.
10. Bever-Mears A. Mistry K. Dieckc FPJ. Cruz E: Zopolrestat prevention of proteinuria, albuminuria, and ca-taractogenesis in diabetes mellitus. Pharmacology 1996:52:292-302.
11. Rakicntcn N, Rakientcn ML, Nad-karni MV: Studies on the diabetogenic action of strcptozotocin (NSC-37917). Cancer Chemother Rep 1963;29:91-98.
12. Follansbec MH. Beyer KH Jr, Griffith JW. Vcsell ES: Studies on pyrazinoylguanidine. 5. Temporal effects over 24 weeks demonstrating attenuation of diabetic nephropathy in ST/.-diabctic rats. Pharmacology 1997:54:241-255.
13. Hammes H-P. Martin S, Federlin K. Geiscn K. Brownlee M: Aminogua-nidine treatment inhibits the development of experimental diabetic nephropathy. Proc Natl Acad Sci USA 1991:88:11555-11558.
14. Srivastava SK. Ansari NH: Prevention of sugar-induced cataracto-genesis in rats by butylated hydroxy-toluene. Diabetes 1988:37:1505-1508.
15. Rink H: Cataractogcnic risk factors. Dev Ophthalmol 1987;15:66-76.
16. The Microalbuminuria Study Group: Caplopril reduces the risk of nephropathy in 1DDM patients with microalbuminuria. Diabetolo-gia 1996;39:587-593.
17. Bron AJ, Sparrow J. Brown NA, Harding JJ, Blakytyn R: The lens in diabetes. Eye 1993:7:260-275.